| Beth Stamp, PT, DPT, PCS | |
|
1500 Wilson Loop, Ward, AR 72176-8656 | |
| (501) 941-5630 | |
| (501) 843-2270 |
| Full Name | Beth Stamp |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 41 Years |
| Location | 1500 Wilson Loop, Ward, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295773919 | NPI | - | NPPES |
| 120359721 | Medicaid | AR | |
| 5S950 | Other | AR | BLUE CROSS BLUE SHEILD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251P0200X | Physical Therapist - Pediatrics | PT1056 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allied Therapy And Consulting Services, Pa | 5597094920 | 11 |
News Archive
IVAX Diagnostics, Inc., a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, pursuant to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.'s suite of diagnostic tests in France. Diamedix is a U.S. subsidiary of IVAX Diagnostics and Delta Biologicals is IVAX Diagnostics' subsidiary located in Italy. The initial term of the distribution agreement is three years.
Obesity is not significantly associated with psychiatric disease course in patients with bipolar disorder (BD), Canadian researchers report.
Girls with Attention Deficit Hyperactivity Disorder (ADHD) - and their families - often look forward to the likely decline in visible symptoms such as fidgety or disruptive behavior as they mature into young women.
Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).
There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.
› Verified 6 days ago
| Provider Name | Allied Therapy And Consulting Services, Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1134185937 PECOS PAC ID: 5597094920 Enrollment ID: O20190911000702 |
News Archive
IVAX Diagnostics, Inc., a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, pursuant to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.'s suite of diagnostic tests in France. Diamedix is a U.S. subsidiary of IVAX Diagnostics and Delta Biologicals is IVAX Diagnostics' subsidiary located in Italy. The initial term of the distribution agreement is three years.
Obesity is not significantly associated with psychiatric disease course in patients with bipolar disorder (BD), Canadian researchers report.
Girls with Attention Deficit Hyperactivity Disorder (ADHD) - and their families - often look forward to the likely decline in visible symptoms such as fidgety or disruptive behavior as they mature into young women.
Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).
There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Beth Stamp, PT, DPT, PCS 420 Chimney Rock Dr, North Little Rock, AR 72120-5846 Ph: (501) 912-6403 | Beth Stamp, PT, DPT, PCS 1500 Wilson Loop, Ward, AR 72176-8656 Ph: (501) 941-5630 |
News Archive
IVAX Diagnostics, Inc., a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, pursuant to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.'s suite of diagnostic tests in France. Diamedix is a U.S. subsidiary of IVAX Diagnostics and Delta Biologicals is IVAX Diagnostics' subsidiary located in Italy. The initial term of the distribution agreement is three years.
Obesity is not significantly associated with psychiatric disease course in patients with bipolar disorder (BD), Canadian researchers report.
Girls with Attention Deficit Hyperactivity Disorder (ADHD) - and their families - often look forward to the likely decline in visible symptoms such as fidgety or disruptive behavior as they mature into young women.
Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).
There is a significant need for objective tests that could improve clinical prediction of future psychosis. One strategy has been to determine whether physiologic measures that are abnormal in people diagnosed with schizophrenia might also be useful in estimating the risk for developing this illness. This is the strategy taken by German and Swiss researchers in the current issue of Biological Psychiatry.
› Verified 6 days ago
Holly Peters, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-588-3211 | |
Mrs. Samantha Cavagnaro, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-941-5630 | |
Meredith Flowers, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-941-5630 | |
Beyond Boundaries, Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2195 Peyton Street, Ward, AR 72176 Phone: 501-941-5630 | |
Nicole C Himmelman, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop Rd, Ward, AR 72176 Phone: 501-941-5630 Fax: 501-843-2270 | |
Chloe Bass, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-588-3211 Fax: 501-353-2599 | |
Whitney Bartley, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 Wilson Loop, Ward, AR 72176 Phone: 501-941-5630 |